KalVista Pharmaceuticals, Inc.KALVNASDAQ
Loading
Operating Cash Flow Growth Under PressureDecelerating
Percentile Rank42
Studio
Year-over-Year Change

Year-over-year operating cash flow growth rate

Percentile
P42
Within normal range
vs 2Y Ago
-19.4x
Contraction
Streak
2 yr
Consecutive declineDecelerating
PeriodValue
2025-71.36%
2024-18.56%
20233.68%
2022-158.97%
202132.68%
2020-23.24%
2019-444.43%
2018144.51%
2017-80.31%
2016-106.60%